Arvinas Inc

Stock Chart, Company Information, and Scan Results

$7.57(as of Jul 22, 9:36 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Arvinas Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$7.57
Ticker SymbolARVN
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees430
CountyUSA
Market Cap$536.5M
EBIDTA-91.4M
10-Day Moving Average7.74
P/E Ratio-11.73
20-Day Moving Average7.72
Forward P/E Ratio17.70
50-Day Moving Average7.28
Earnings per Share-0.66
200-Day Moving Average15.30
Profit Margin43.91%
RSI48.05
Shares Outstanding73.0M
ATR0.44
52-Week High30.31
Volume1,882,289
52-Week Low5.90
Most Recent Support Level7.32
Book Value660.1M
Most Recent Resistance Level7.93
P/B Ratio0.83
Upper Keltner8.71
P/S Ratio1.28
Lower Keltner6.73
Debt-to-Equity Ratio8.71
Next Earnings Date07/28/2025
Cash Surplus-133.0M
Next Ex-Dividend DateUnknown

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Arvinas Inc In Our Stock Scanner

example chart graphic
Date: Jul 22, 2025Scan Name: Low PS RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 22, 2025Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 22, 2025Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 22, 2025Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 22, 2025Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 22, 2025Scan Name: Falling WedgeScan Type: Chart Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.